Plain-English translation of NCT03326310 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing whether , a new medication, works safely when combined with in people with certain serious blood cancers like myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasms, and myelofibrosis. Researchers are starting with lower doses of the new medication to find the highest dose that can be given safely alongside the standard medication.
Current treatments don't work well enough for all patients with these blood cancers, and some patients can't tolerate existing therapies. This trial explores whether combining this medication with an established treatment might help more patients.
You likely qualify if…
You likely don't qualify if…
You would receive by injection under your skin on days 1 through 7 of each 28-day cycle, followed by the new medication by mouth on days 8 through 21. You would continue this repeating schedule as long as your disease is stable and you tolerate the treatment well. The study involves frequent blood tests and clinic visits to monitor how you respond and watch for any side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States